BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: He S, Lockart I, Alavi M, Danta M, Hajarizadeh B, Dore GJ. Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma. Aliment Pharmacol Ther 2020;51:34-52. [DOI: 10.1111/apt.15598] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Shih WL, Fang CT, Chen PJ. Chapter XX Antiviral Treatment and Cancer Control. Recent Results Cancer Res 2021;217:325-54. [PMID: 33200371 DOI: 10.1007/978-3-030-57362-1_13] [Reference Citation Analysis]
2 Cieciura T, Urbanowicz A, Foroncewicz B, Hryniewiecka E, Pączek L, Ciszek M. Hepatocellular Carcinoma Is a Negative Predictor of Sustained Viral Response in Liver Transplant Recipients With Hepatitis C Treated With Direct-Acting Antivirals. Transplant Proc 2020;52:2450-3. [PMID: 32241637 DOI: 10.1016/j.transproceed.2020.01.098] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Lockart I, Hajarizadeh B, Alavi M, Davison S, Prakoso E, Levy MT, George J, Dore GJ, Danta M. Hepatitis C virus cure before hepatocellular carcinoma diagnosis is associated with improved survival. J Viral Hepat 2021;28:710-8. [PMID: 33481322 DOI: 10.1111/jvh.13475] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Lockart I, Hajarizadeh B, Buckley N, Davison S, Prakoso E, Levy MT, George J, Dore GJ, Danta M. All-cause hepatocellular carcinoma survival in the era of direct-acting antiviral therapy. J Gastroenterol Hepatol 2021. [PMID: 34520088 DOI: 10.1111/jgh.15687] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Halota W, Flisiak R, Juszczyk J, Małkowski P, Pawłowska M, Simon K, Tomasiewicz K. Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2020. Clin Exp Hepatol 2020;6:163-9. [PMID: 33145422 DOI: 10.5114/ceh.2020.98606] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
6 Ridruejo E, Piñero F, Mendizabal M, Cheinquer H, Wolff FH, Anders M, Reggiardo V, Ameigeiras B, Palazzo A, Alonso C, Schinoni MI, Zuain MGV, Tanno F, Figueroa S, Santos L, Peralta M, Soza A, Vistarini C, Adrover R, Fernández N, Perez D, Hernández N, Estepo C, Bruno A, Descalzi V, Sixto M, Borzi S, Cocozzella D, Zerega A, Araujo A, Varón A, Silva M; Latin American Liver Research Educational and Awareness Network (LALREAN). Decompensated cirrhosis and liver transplantation negatively impact in DAA treatment response: Real‐world experience from HCV‐LALREAN cohort. J Med Virol 2020;92:3545-55. [DOI: 10.1002/jmv.26383] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
7 Chiu HC, Chiu YC, Yang EH, Chang TT, Chien SC, Wu IC, Wu CH, Cheng PN. Effectiveness and safety of ledipasvir/sofosbuvir for genotype 2 chronic hepatitis C infection: Real-world experience from Taiwan. J Formos Med Assoc 2021;120:983-90. [PMID: 32891488 DOI: 10.1016/j.jfma.2020.08.033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Torre P, Aglitti A, Masarone M, Persico M. Viral hepatitis: Milestones, unresolved issues, and future goals. World J Gastroenterol 2021; 27(28): 4603-4638 [PMID: 34366625 DOI: 10.3748/wjg.v27.i28.4603] [Reference Citation Analysis]
9 Pawlotsky J, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, Marra F, Puoti M, Wedemeyer H. EASL recommendations on treatment of hepatitis C: Final update of the series☆. Journal of Hepatology 2020;73:1170-218. [DOI: 10.1016/j.jhep.2020.08.018] [Cited by in Crossref: 113] [Cited by in F6Publishing: 102] [Article Influence: 113.0] [Reference Citation Analysis]
10 Stanciu C, Muzica CM, Girleanu I, Cojocariu C, Sfarti C, Singeap AM, Huiban L, Chiriac S, Cuciureanu T, Trifan A. An update on direct antiviral agents for the treatment of hepatitis C. Expert Opin Pharmacother 2021;22:1729-41. [PMID: 33896315 DOI: 10.1080/14656566.2021.1921737] [Cited by in F6Publishing: 1] [Reference Citation Analysis]